{
  "id": "658d437d-e474-4a65-90ca-65e09a4be45b",
  "title": "Corvus Pharmaceuticals outlines clinical milestones for soquelitinib in 2025",
  "link": "https://seekingalpha.com/news/4425118-corvus-pharmaceuticals-outlines-clinical-milestones-for-soquelitinib-in-2025?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Tue, 25 Mar 2025 19:58:48 -0400",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "crvs"
  ],
  "byline": "SA Transcript Insights Editor",
  "length": 1055,
  "excerpt": "Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust financial...",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "Earnings Call Insights: Corvus Pharmaceuticals (CRVS) Q4 2024 Management View CEO Richard Miller detailed the progress of soquelitinib, emphasizing its potential as a first-in-class oral therapy for immune diseases and cancers. He highlighted the 39% objective response rate from the Phase 1 trialSeeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.",
  "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003c/header\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cp\u003eEarnings Call Insights: Corvus Pharmaceuticals (CRVS) Q4 2024\u003c/p\u003e \u003ch3\u003eManagement View\u003c/h3\u003e \u003cul\u003e\u003cli\u003eCEO Richard Miller detailed the progress of soquelitinib, emphasizing its potential as a first-in-class oral therapy for immune diseases and cancers. He highlighted the 39% objective response rate from the Phase 1 trial\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003cp\u003e\u003cstrong\u003eSeeking Alpha\u0026#39;s Disclaimer: \u003c/strong\u003eThe earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts \u003ca href=\"https://seekingalpha.com/symbol/CRVS/earnings/transcripts\"\u003ehere\u003c/a\u003e. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "2 min read",
  "publishedTime": "2025-03-25T23:58:48Z",
  "modifiedTime": null
}
